Hims & Hers Health has introduced five compounded peptide and longevity treatments in the United States through a new Peptides+ telehealth platform. None of the company's specific compounded formulations has FDA approval.
The starting lineup is sermorelin, glutathione, nicotinamide adenine dinucleotide (NAD+), vitamin B-12 and L-carnitine. Sermorelin stimulates growth hormone release, glutathione is an antioxidant associated with cellular protection, NAD+ supports cellular metabolism, B-12 contributes to red blood cell production and nerve function, and L-carnitine helps the body convert fat into energy.
The demand is already there
A company spokesperson said more than 10,000 people joined the early-access waiting list within 15 days of its launch in late October. Hims said the products are manufactured by licensed US pharmacies subject to state pharmacy board oversight, describing those facilities as adhering to "rigorous quality standards."
The process starts with an assessment of medical history, current medications and health goals, with independent licensed providers determining eligibility and dosage. Chief Medical Officer Dr. Anant Vinjamoori said people with serious cardiovascular, liver or kidney disease would not qualify at this stage.
What the company admits it does not know
The most useful line in the whole announcement comes from Hims itself. "We don't have all of this data that we're used to having with compounds like this," Vinjamoori told CNBC, adding that follow-up could involve dose adjustments, alternative compounds or referrals elsewhere.
That candor is worth noting, and it sits awkwardly next to the plan to add BPC-157 and TB-500. Both are unapproved, both are marketed for healing and soft-tissue recovery, and much of the available research on them has involved animals rather than human participants.
Researchers push back on dosing
Joshua Kritzer, a chemistry professor at Tufts University, said peptides should be viewed "the same way you would view any drug that hasn't been rigorously tested," and that anecdotal reports are "just not enough information to put a substance in your body."
Paul Knoepfler of UC Davis Health went at the dosing question directly, saying "the dosing for these products really has not been established" and warning that excessive exposure to synthetic peptides could trigger unexpected immune reactions.
Bottom line
Hims is betting that physician oversight and licensed compounding pharmacies close the gap that clinical trials have not. The researchers quoted say the gap is dosing, and nobody in this story claims it has been settled.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.